Introduction

Osteopenia, which is defined as a decrease in bone mineral density, has been recently recognized as a metabolic and an oncological biomarker for surgery in patients with malignancy. We aimed to study the prognostic impact of osteopenia in patients with pancreatic cancer (PC) after resection.

Methods

A total of 56 patients who underwent curative resection of PC were retrospectively investigated. The skeletal muscle index at the third lumbar spine and bone mineral density at the 11th thoracic vertebra were measured using computed tomography.

Results

Sarcopenia and osteopenia were identified in 24 (43%) and 27 (48%) patients, respectively. The overall and disease-free survival rates were significantly lower in the sarcopenia group than in the non-sarcopenia group (p < 0.01 and p < 0.01, respectively) and in the osteopenia group than in the non-osteopenia group (p < 0.01 and p < 0.01, respectively). In multivariate analysis, sarcopenia (odds ratio [OR] 4.05; 95% confidence interval [CI] 1.23–13.38; p = 0.02) was a significant independent predictor of 1-year disease-free survival. Further, sarcopenia (OR 6.00; 95% CI 1.46–24.6; p = 0.01) and osteopenia (OR 4.66; 95% CI 1.15–18.82; p = 0.03) were significant independent predictors of 2-year overall survival.

Conclusion

Osteopenia is a significant negative factor for 2-year overall survival after curative resection of PC.

中文翻译：

---

骨质减少对胰腺癌患者手术和肿瘤学结果的影响

介绍

骨质减少被定义为骨矿物质密度的降低，最近被认为是恶性肿瘤患者手术的代谢和肿瘤生物标志物。我们旨在研究骨量减少对胰腺癌 (PC) 患者切除术后的预后影响。

方法

总共 56 名接受 PC 根治性切除术的患者进行了回顾性研究。使用计算机断层扫描测量第三腰椎的骨骼肌指数和第 11 胸椎的骨矿物质密度。

结果

分别在 24 (43%) 和 27 (48%) 名患者中发现了肌肉减少症和骨质减少症。肌肉减少症组的总生存率和无病生存率显着低于非肌肉减少症组（分别为p  < 0.01 和p  < 0.01）和骨质减少症组低于非骨质减少症组（p  < 0.01 和p < 0.01）p  < 0.01，分别）。在多变量分析中，肌肉减少症（比值比 [OR] 4.05；95% 置信区间 [CI] 1.23–13.38；p  = 0.02）是 1 年无病生存率的重要独立预测因子。此外，肌肉减少症（OR 6.00；95% CI 1.46–24.6；p  = 0.01）和骨质减少症（OR 4.66；95% CI 1.15–18.82；p = 0.03) 是 2 年总生存率的显着独立预测因子。

结论

骨质减少是 PC 根治性切除术后 2 年总生存率的显着负面因素。